These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29773661)

  • 41. Multicystic and diffuse malignant peritoneal mesothelioma in children.
    Vermersch S; Arnaud A; Orbach D; Andre N; Berger C; Kepenekian V; Brigand C; Fresneau B; Poli-Merol ML; Habougit C; Varlet F; Scalabre A
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28286. PubMed ID: 32277799
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
    van Zandwijk N; Pavlakis N; Kao SC; Linton A; Boyer MJ; Clarke S; Huynh Y; Chrzanowska A; Fulham MJ; Bailey DL; Cooper WA; Kritharides L; Ridley L; Pattison ST; MacDiarmid J; Brahmbhatt H; Reid G
    Lancet Oncol; 2017 Oct; 18(10):1386-1396. PubMed ID: 28870611
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases.
    Yang A; Zhang Z; Chaurasiya S; Park AK; Jung A; Lu J; Kim SI; Priceman S; Fong Y; Woo Y
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37019471
    [TBL] [Abstract][Full Text] [Related]  

  • 44. IMP3 as a prognostic biomarker in patients with malignant peritoneal mesothelioma.
    Hui S; Guo-Qi Z; Xiao-Zhong G; Chun-Rong L; Yu-Fei L; Dong-Liang Y
    Hum Pathol; 2018 Nov; 81():138-147. PubMed ID: 30031101
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.
    Galanis E; Hartmann LC; Cliby WA; Long HJ; Peethambaram PP; Barrette BA; Kaur JS; Haluska PJ; Aderca I; Zollman PJ; Sloan JA; Keeney G; Atherton PJ; Podratz KC; Dowdy SC; Stanhope CR; Wilson TO; Federspiel MJ; Peng KW; Russell SJ
    Cancer Res; 2010 Feb; 70(3):875-82. PubMed ID: 20103634
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers.
    Haddad D; Chen N; Zhang Q; Chen CH; Yu YA; Gonzalez L; Aguilar J; Li P; Wong J; Szalay AA; Fong Y
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S665-74. PubMed ID: 22258815
    [TBL] [Abstract][Full Text] [Related]  

  • 47. JX-594, a targeted oncolytic poxvirus for the treatment of cancer.
    Merrick AE; Ilett EJ; Melcher AA
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1372-82. PubMed ID: 19943208
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis.
    Bella Á; Arrizabalaga L; Di Trani CA; Gonzalez-Gomariz J; Gomar C; Russo-Cabrera JS; Olivera I; Cirella A; Fernandez-Sendin M; Alvarez M; Teijeira A; Atay C; Medina-Echeverz J; Hinterberger M; Hochrein H; Melero I; Berraondo P; Aranda F
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37918917
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Well-differentiated papillary mesothelioma with invasive foci.
    Churg A; Allen T; Borczuk AC; Cagle PT; Galateau-Sallé F; Hwang H; Murer B; Murty VV; Ordonez N; Tazelaar HD; Wick M
    Am J Surg Pathol; 2014 Jul; 38(7):990-8. PubMed ID: 24618613
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of Different Oncolytic Vaccinia Virus Strains for the Treatment of Murine Peritoneal Mesothelioma.
    Yurttas C; Beil J; Berchtold S; Smirnow I; Kloker LD; Sipos B; Löffler MW; Königsrainer A; Mihaljevic AL; Lauer UM; Thiel K
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254857
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients.
    Streby KA; Geller JI; Currier MA; Warren PS; Racadio JM; Towbin AJ; Vaughan MR; Triplet M; Ott-Napier K; Dishman DJ; Backus LR; Stockman B; Brunner M; Simpson K; Spavin R; Conner J; Cripe TP
    Clin Cancer Res; 2017 Jul; 23(14):3566-3574. PubMed ID: 28495911
    [No Abstract]   [Full Text] [Related]  

  • 52. Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs.
    Béguin J; Gantzer M; Farine I; Foloppe J; Klonjkowski B; Maurey C; Quéméneur É; Erbs P
    Sci Rep; 2021 Jan; 11(1):2209. PubMed ID: 33500518
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model.
    Kuryk L; Haavisto E; Garofalo M; Capasso C; Hirvinen M; Pesonen S; Ranki T; Vassilev L; Cerullo V
    Int J Cancer; 2016 Oct; 139(8):1883-93. PubMed ID: 27287512
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis.
    Helm JH; Miura JT; Glenn JA; Marcus RK; Larrieux G; Jayakrishnan TT; Donahue AE; Gamblin TC; Turaga KK; Johnston FM
    Ann Surg Oncol; 2015 May; 22(5):1686-93. PubMed ID: 25124472
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Next-generation oncolytic vaccinia vectors.
    Thorne SH
    Methods Mol Biol; 2012; 797():205-15. PubMed ID: 21948478
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current trends in the management of malignant peritoneal mesothelioma.
    Miura JT; Johnston FM; Gamblin TC; Turaga KK
    Ann Surg Oncol; 2014 Nov; 21(12):3947-53. PubMed ID: 24841356
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy.
    Lee M; Alexander HR; Burke A
    Pathology; 2013 Aug; 45(5):464-73. PubMed ID: 23846294
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
    Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
    Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treating peritoneal mesothelioma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. A case series and review of the literature.
    Stamou K; Tsamis D; Pallas N; Samanta E; Courcoutsakis N; Prassopoulos P; Tentes AA
    Int J Hyperthermia; 2015; 31(8):850-6. PubMed ID: 26382910
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
    Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
    Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.